Our proteomic profiling reveals a notable decrease in cytoplasmic GPD1 levels, indicating a potential reduction in mitochondrial oxidation of NADH from the cytosol and its consequent impact on triglyceride metabolism in dysferlinopathy. The gene discussed is GPD1; the disease is neuromuscular disease caused by qualitative or quantitative defects of dysferlin.